“Patient Voice” Report Puts Chronic Fatigue Symptoms, Treatments In Benefit/Risk Framework
Executive Summary
FDA report on CFS/myalgic encephalomyelitis is first of its kind from the patient-focused drug development initiative under PDUFA V. Incorporating comments from hundreds of patients and caregivers into a structured framework shows how the input may support a benefit/risk assessment for new products.
You may also be interested in...
FDA Ends Regularly Scheduled Patient-Focused Drug Development Meetings
After conducting 24 disease-focused meetings in five years, FDA moving to next phase of patient interaction under new user fee cycle.
US FDA Faces Hiring Slowdown, Funding Cuts In Trump's FY 17 Plan
Suggested cuts to appropriations bill funding government for remainder of fiscal year 2017 also includes 'administrative savings.'
Hemispherx 'Redoubling' US Efforts On Ampligen
Chronic fatigue drug received two FDA complete response letters, but company now agrees to additional study, new CEO says. Firm hopes Argentine approval also bodes well.